By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Genentech 

1 DNA Way

South San Francisco  California  94080-4990  U.S.A.
Phone: 650-225-1000 Fax: 650-225-6000


SEARCH JOBS

Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.

On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.

Please view our company video on YouTube:
http://www.youtube.com/genentech#p/u/1/GJH4X5gxxf0

Connect with us via Social Media:

Facebook: www.facebook.com/GenentechJobs

Twitter: www.twitter.com/GenentechJobs

LinkedIn: www.linkedin.com/company/genentech



YEAR FOUNDED:

1976

LEADERSHIP:

CEO: Ian T. Clark

CEO: Ed Harrington

Chief Medical Officer: Sandra J. Horning, MD

Chief Compliance Officer: Frederick C. Kentz, III

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email:
Ownership: Subsidiary

Web Site: Genentech
Employees: 10,000+
Symbol: RHHBY
 



Industry
Biotechnology

Segment
Biotherapeutics





Company News
FDA Approves Genentech (RHHBY)’s Avastin (Bevacizumab) Plus Chemotherapy For A Specific Type Of Advanced Ovarian Cancer 12/7/2016 10:08:05 AM
Genentech (RHHBY)’s Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared To Rituxan 12/5/2016 11:54:44 AM
Genentech (RHHBY) Braces for Competition From Amgen (AMGN)-Allergan (AGN) for Best-Selling Drug Avastin 11/17/2016 6:22:06 AM
Phase III GiACTA Study Shows Genentech (RHHBY)’s Actemra Is Superior To Steroids Alone In Maintaining Steroid-Free Remission For People With Giant Cell Arteritis 11/14/2016 10:03:22 AM
With Bristol-Myers Squibb (BMY), Genentech (RHHBY) and Merck & Co. (MRK) Expanding in the Bay Area, Some Wonder if the Real Estate Boom is Too Much 11/14/2016 6:02:49 AM
Genentech (RHHBY) Snaps Up Four Buildings it Had Been Leasing Since 2006 11/10/2016 7:13:04 AM
Genentech (RHHBY) Showcases New Clinical Data Across A Variety Of Blood Diseases At American Society of Hematology 2016 Annual Meeting 11/3/2016 11:34:29 AM
With New Owners, Ambrx, Inc. Aims To Challenge Genentech (RHHBY) 11/3/2016 7:44:23 AM
FDA Accepts Genentech (RHHBY)'s Biologics License Application For Subcutaneous Formulation Of Rituximab 11/3/2016 6:47:41 AM
Genentech (RHHBY) To Present New Data On Medicines For Autoimmune Diseases And Severe Inflammatory Disorders At The 2016 American College of Rheumatology/ARHP Annual Meeting 11/2/2016 10:31:35 AM
12345678910...
//-->